Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Myriad Genetic Laboratories, Inc..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,407actual
Sites
214
Countries
Austria, Belgium, Brazil +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-01-04 | actual | When the study began enrolling |
| Primary completion | 2025-03-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-23 | estimated | The whole study's end, after follow-up |
| First posted | 2018-11-09 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-09 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Ovarian Cancer
Interventions
- Drug: Bevacizumab
- Drug: Durvalumab
- Drug: Olaparib
- Drug: Placebo olaparib
- Drug: Durvalumab placebo
- Drug: Carboplatin+Paclitaxel
Primary outcomes
what the primary-completion date above is the date OFProgression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
measured At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)
measured At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-04-24 · 6.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2021-09-02 · 2.9 MB · SAP_001.pdf
Publications
- PMID 37185961 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed